Eurofins announces its Investment Grade credit rating assigned by Moody’s

Eurofins announces its Investment Grade credit rating assigned by Moody’s

Eurofins Scientific (ERF FP), a global leader in bioanalytical testing, announces today that it has received its first public long-term issuer credit rating by Moody’s Investor Services (“Moody’s”) which assigned an investment grade rating of Baa3 with a stable outlook.

Eurofins has been active in the debt capital markets for many years as one of the major unrated issuers in Europe with a solid track record. With this initial public credit rating, Eurofins should have access to a broader investor base and even better conditions from debt capital markets.

Comment from Moody’s analyst, Perrine Bajolle: “The Baa3 rating assigned to Eurofins reflects the company’s diversified and well-established market position in the bioanalytical testing sector and its track record of gradual operating performance improvement supported by organic and external growth”.

Comment from the CEO, Dr. Gilles Martin: “This credit rating acknowledges Eurofins’ successful growth strategy, its leadership positions in most of its activities and its underlying resilient end-markets. Having just concluded a phase of significant investments, building organically and through acquisitions a global best-in-class laboratories network, Eurofins has reached a size and level of maturity which enables more focus on innovation-fueled organic growth. From this solid base, the Group intends to keep its disciplined financial policy aimed at generating significant value for shareholders while delivering unique solutions for its clients and sustaining revenues, margins and cashflows growth”.

Eurofins Scientific will release its half-year results on 06 August 2020.

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

1 2 3 4